UK markets closed
NIKKEI 225
38,274.05 -131.61 (-0.34%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
79.43 -2.50 (-3.05%) GOLD FUTURES
2,315.20 +12.30 (+0.53%) DOW
37,929.51 +113.59 (+0.30%) Bitcoin GBP
45,780.68 -2,528.37 (-5.23%)
MRK Jan 2025 92.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:27AM EDT. Market open.
| Previous close | 37.75 |
| Open | 37.75 |
| Bid | 37.95 |
| Ask | 39.35 |
| Strike | 92.50 |
| Expiry date | 2025-01-17 |
| Day's range | 37.75 - 37.75 |
| Contract range | N/A |
| Volume | |
| Open interest | 146 |
Business WireMerck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
RAHWAY, N.J., May 01, 2024--Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer
Insider MonkeyMerck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.07, expectations were $1.94. Merck & Co., Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank […]
Business WireMerck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
RAHWAY, N.J., April 29, 2024--Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
© 2024 Yahoo. All rights reserved.